InvestorsHub Logo
Followers 7
Posts 559
Boards Moderated 0
Alias Born 03/05/2010

Re: None

Thursday, 10/19/2023 3:22:30 PM

Thursday, October 19, 2023 3:22:30 PM

Post# of 391
Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company committed to developing novel, transformative therapies for serious metabolic and rare diseases, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) eligibility to RZ358 for the treatment of congenital hyperinsulinism (HI).

Read 8k yesterday news

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RZLT News